Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ironwood Has Revised Its FY 2024 Financial Guidance Due To Continued Linzess Pricing Pressure Due To Higher-than-expected Medicaid Utilization Trends For FY 2024, It Expects Sales Of $350M-$375M Compared To Prior Range Of $405M-$425M And Consensus Of $410.05M

Author: Benzinga Newsdesk | August 08, 2024 07:08am

Prior 2024 Guidance (May 9, 2024)	Revised 2024 Guidance (August 8, 2024)
U.S. LINZESS Net Sales	Mid-single digits % decline2
Total Revenue	$405 - $425 million
Adjusted EBITDA1	>$120 million Excludes potential CNP-104 option exercise

Posted In: IRWD